Search Results

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.com.au/expertise/influenza/pandemic-response-solutions

CSL Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.cslseqirus.com.au/manufacturing/global-manufacturing-network

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.com.au/expertise

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’.

https://www.cslseqirus.com.au/news/csl-seqirus-vaccine-and-antivenom-manufacturing-facility-in-australia-construction-milestone

Cell-based influenza vaccines demonstrated between 10% and 15% relative vaccine effectiveness across three recent seasons compared to traditional egg-based vaccines in the prevention of test-confirmed influenza, according to a new study presented at ESWI Influenza Conference in Spain.

https://www.cslseqirus.com.au/news/cell-based-flu-vaccines-demonstrate-superior-effectiveness-as-csl-builds-manufacturing-in-melbourne

With summer fast approaching, new research released today on National Venomous Bites and Stings Day reveals that many Australians are missing vital venomous bites and stings first aid knowledge.

https://www.cslseqirus.com.au/news/new-research-reveals-what-australians-arent-prepared-for-this-summer

CSL Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.cslseqirus.com.au/our-company/corporate-responsibility/disclosures

Read the latest news from CSL Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.com.au/news/csl-seqirus-private-market-influenza-vaccines-now-available-as--australia-sees-early-rise-flu-cases

33% of Australian adults say that flu is only somewhat serious (while it can get people very sick and put in hospital, they cannot die from it). 14% say it’s not very, or not at all, serious1.

https://www.cslseqirus.com.au/news/new-research-has-experts-concerned-australians-are-still-too-complacent-about-flu

CSL Seqirus and Amarin sign licensing agreement to commercialise Vazkepa (icosapent ethyl) in Australia and New Zealand

https://www.cslseqirus.com.au/news/vazkepa-licensing-agreement